VW

Vanessa Waddell

Interim CEO

PolyActiva

Melbourne, Victoria


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
PolyActiva
Industry
research
Employees
21.0
Seniority
C suite
Annual Revenue
7000000.0
Total Funding
9864770.0
Latest Funding
Series B

Technologies

Route 53 Outlook Microsoft Office 365 Mobile Friendly Typekit WordPress.org Google Font API Nginx reCAPTCHA Android Python Node.js SharePoint Flutter Basis IoT

Keywords

polymer chemistry drug delivery ophthalmology biotechnology life sciences biotechnology research biodegradable implants sustained drug delivery ophthalmic medicine glaucoma treatment controlled drug release ocular implants drug delivery technology polymer technology prezia delivery system sustained therapy intraocular pressure iop reduction phase ii clinical trials ocular hypertension post-operative infection prevention antimicrobial implants micro-invasive glaucoma surgery patient compliance long-term drug delivery safety profile biocompatibility injectable gels topical films custom drug combinations rapid biodegradation ophthalmology innovations chronic eye disease medical devices clinical research drug-monomer conjugates fda approval prodrug formulations treatment adherence sustained release technology ocular surgery patient outcomes improvement vision restoration laser treatment ocular pharmacotherapy pharmaceutical development clinical trial objectives treatment efficacy biodegradable drug delivery anti-inflammatory implants hcp integration targeted drug delivery ophthalmic application treatment burden reduction ophthalmology solutions hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans